Canada Approves Osiris Stem-Cell Therapy

May 2012
MondayMorning;5/21/2012, Vol. 20 Issue 21, p1
The article informs that Health Canada has approved stem-cell therapy Prochymal of Osiris Therapeutics Inc. for use against graft vs. host disease, a condition in which transplanted bone marrow cells attack the body of the patient. It has been informed that marketing of Prochymal has not been approved in the U.S., but the Food and Drug Administration (FDA) has allowed its use in treatment of both adults and children with graft vs. host disease after failure of steroids.


Related Articles

  • Osiris Sees Prochymal Promise Despite Woes.  // Bioworld Week;9/14/2009, Vol. 17 Issue 37, p3 

    The article reports on the optimism of Columbia, Maryland-based Osiris Therapeutics Inc. on the success of the phase III trial of its stem cell product Prochymal. It notes president and chief executive officer (CEO) Randal Mills indicating that Osiris continues its commitment to make Prochymal...

  • Osiris Therapeutics Reports 2nd Quarter 2012 Financial Results.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article reports about financial results of Osiris Therapeutics Inc. for second Quarter of 2012. It highlights the results including first approval from Health Canada for marketing of stem cell drug, Prochymal, attainment of transitional pass-through status from the Center for Medicare &...

  • Drug approval system questioned in US and Canada. Egertson, Laura // CMAJ: Canadian Medical Association Journal;2/1/2005, Vol. 172 Issue 3, p317 

    Reports on the plans of Health Canada to consider implementing pilot activities that would allow for concurrent reviews of drugs in Canada and the U.S. in 2005. Objectives of a memorandum of understanding between the U.S. and Canada in which the joint reviews would take place; Criticism of the...

  • FDA fastest in granting new drug approvals among major regulators including EMA, TGA, Health Canada. Rosenberg, Ronald // CenterWatch Weekly;2/2/2015, Vol. 19 Issue 4, p1 

    The article offers information on the report from Center for Innovation in Regulatory Science (CIRS) which indicated that the U.S. Food and Drug Administration (FDA) was the fastest in approving drugs among major regulatory agencies worldwide. Topics discussed include factors affecting the...

  • FDA ban of generic oxycodone calls into question Health Canada's approval.  // CMAJ: Canadian Medical Association Journal;6/11/2013, Vol. 185 Issue 9, pE381 

    The article presents information on the criticism faced by Health Canada, department of the government of Canada, for its approval of generic oxycodone after the U.S. Food and Drug Administration (FDA) decided to ban generic versions of the drug due to its abuse across North America. According...

  • The darker side of stem cells.  // Nature;3/1/2012, Vol. 483 Issue 7387, p5 

    The author reflects on the provision of unproven stem-cell treatments to patients in Texas, which involves Celltex Therapeutics. The author states that injection of unapproved adult stem cells into patients is considered a crime by the U.S. Food and Drug Administration (FDA). The author notes...

  • Stem Cell Sector Gets a Healthy Shot in the Arm. Winter, Peter // BioWorld Insight;6/4/2012, Vol. 20 Issue 23, p1 

    The article discusses the approval of the drug Prochymal manufactured by Osiris Therapeutics Inc. which provides allogeneic stem cell treatment for graft versus host disease (GvHD) in children. It mentions Health Canada's decision as the world's first regulatory approval of a manufactured stem...

  • World's First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal.  // Biomedical Market Newsletter;5/18/2012, Vol. 21, p1 

    The article offers information on the stem cell therapy, Prochymal developed by Osiris Therapeutics Inc. which has received the market authorization from Health Canada. It further informs that the therapy is used for the treatment of acute graft-versus-host disease (GvHD) in children. It...

  • Decisions Update.  // PharmaWatch: Biotechnology;Oct2009, Vol. 8 Issue 10, p12 

    The article offers developments related drug approval decisions. Shire Pharmaceuticals Group PLC has obtained the approval from the U.S. Food and Drug Administration (FDA) for Intuniv for attention-deficit/hyperactivity disorder (ADHD). Theravance Inc. and Astellas Pharma US Inc. unveiled that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics